Adiponectin Paradox as a Therapeutic Target in Alzheimer's Disease

9Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Despite the apparent neurotoxicity of amyloid-ß (Aß), recent clinical trials of Aß immunotherapy have not shown any clinical benefit in Alzheimer's disease (AD). Given this, clarification of the next generation therapeutic strategy in AD is warranted. Hypothetically, adiponectin might be involved in promoting amyloidogenic evolvability in reproduction, which may result in the adiponectin paradox through antagonistic pleiotropy mechanism in aging, leading to AD. Accordingly, preventing the adiponectin paradox by suppressing adiponectin signaling might prove therapeutic in AD.

Cite

CITATION STYLE

APA

Waragai, M., Ho, G., Takamatsu, Y., Wada, R., Sugama, S., Takenouchi, T., … Hashimoto, M. (2020). Adiponectin Paradox as a Therapeutic Target in Alzheimer’s Disease. Journal of Alzheimer’s Disease, 76(4), 1249–1253. https://doi.org/10.3233/JAD-200416

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free